Exploring HER2-low disease: Does it impact breast cancer survival?

被引：0
|
作者：
Lopez-Paradis, Assumpcio
Pous, Anna
Bernat-Peguera, Adria
Quiroga, Vanesa
Cirauqui, Beatriz
Felip, Eudald
Bergamino, Milana
Ferrando-Diez, Angelica
Romeo, Marga
Teruel, Iris
Martinez-Cardus, Anna
Margeli, Mireia
机构：
[1] Univ Autonoma Barcelona, B ARGO, Dept Med Oncol, Catalan Inst Oncol ICO Badalona, Badalona 08916, Barcelona, Spain
[2] Univ Autonoma Barcelona, IGTP Hlth Res Inst Germans Trias i Pujol, Badalona 08916, Barcelona, Spain
[3] Catalan Inst Oncol, Dept Oncol, Barcelona, Spain
[4] Badalona Appl Res Grp Oncol B ARGO Grou, Barcelona, Spain
[5] Inst Catal Oncol ICO Badalona, Dept Med Oncol, B ARGO, Barcelona, Spain
[6] Univ Autonoma Barcelona, Germans Trias & Pujol Res Inst Badalona, Germans Trias & Pujol Univ Hosp, Dept Med Oncol,Catalan Inst Oncol Badalona,Badalo, Badalona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
577
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The impact of the HER2-low status on conditional survival in patients with breast cancer
    Ma, Teng
    Liu, Changgen
    Ma, Tianyi
    Sun, Xinyi
    Cui, Jian
    Wang, Lulu
    Mao, Yan
    Wang, Haibo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [2] Survival outcomes for HER2-low breast cancer: Danish national data
    Sode, Michael
    Nielsen, Kare
    Jensen, Maj-Britt
    Berg, Tobias
    Knoop, Ann
    Ejlertsen, Bent
    Laenkhol, Anne-Vibeke
    ACTA ONCOLOGICA, 2024, 63 : 878 - 886
  • [3] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Schnog, John-John B.
    Samson, Michael J.
    Duits, Ashley J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12): : 1143 - 1144
  • [4] Biology and Treatment of HER2-Low Breast Cancer
    Nicolo, Eleonora
    Tarantino, Paolo
    Curigliano, Giuseppe
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 117 - 132
  • [5] HER2-Low Breast Cancer: a New Subtype?
    Chiara Corti
    Federica Giugliano
    Eleonora Nicolò
    Paolo Tarantino
    Carmen Criscitiello
    Giuseppe Curigliano
    Current Treatment Options in Oncology, 2023, 24 : 468 - 478
  • [6] Clinical Significance of HER2-low Breast Cancer
    Zaiem, Fadi
    AbuJamea, Asem
    Kheil, Mira
    Numi, Anna
    Abbas, Omar
    Awada, Sanaa
    Almsaddi, Ragad
    Al-Juburi, Saleh
    Larson, Lauren
    Jain, Deepti
    AlSaghir, Maya
    Jang, Hyejeong
    Kim, Seongho
    Bandyopadhyay, Sudeshna
    Jaiman, Sunil
    Ali-Fehmi, Rouba
    CANCER RESEARCH, 2024, 84 (09)
  • [7] HER2-low breast cancer: where are we?
    Molinelli, Chiara
    Jacobs, Flavia
    Marchio, Caterina
    Pitto, Francesca
    Cosso, Maurizio
    Spinaci, Stefano
    de Azambuja, Evandro
    Schettini, Francesco
    Agostinetto, Elisa
    Lambertini, Matteo
    BREAST CARE, 2022, 17 (06) : 533 - 544
  • [8] Epidemiology of HER2-low breast cancer in Lithuania
    Cesas, A.
    Poskiene, L.
    Valkiuniene, R. B.
    Radvinskiene, L.
    Lege, I.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 103 - 104
  • [9] HER2-Low Breast Cancer: a New Subtype?
    Corti, Chiara
    Giugliano, Federica
    Nicolo, Eleonora
    Tarantino, Paolo
    Criscitiello, Carmen
    Curigliano, Giuseppe
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (05) : 468 - 478
  • [10] HER2-Low Breast Cancer: Now and in the Future
    Kang, Sora
    Kim, Sung-Bae
    CANCER RESEARCH AND TREATMENT, 2024, 56 (03): : 700 - 720
12345